L V Beex
Overview
Explore the profile of L V Beex including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
548
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Barnes D, Millis R, Beex L, Thorpe S, Leake R
Eur J Cancer
. 1999 Jan;
34(11):1677-82.
PMID: 9893651
This paper outlines the changes which have occurred over the last 25 years in the methods employed for the measurement of oestrogen receptors to aid the management of women with...
12.
van Kuilenburg A, Vreken P, Beex L, De Abreu R, van Gennip A
J Inherit Metab Dis
. 1998 Aug;
21(3):280-4.
PMID: 9686375
No abstract available.
13.
Bruning P, Bonfrer J, Paridaens R, Nooij M, Klijn J, Beex L, et al.
Anticancer Drugs
. 1998 Jul;
9(5):419-25.
PMID: 9660539
The new non-steroidal aromatase inhibitor vorozole (R83842) was administered orally at a single daily dose of 2.5 mg to 27 postmenopausal women with advanced breast cancer in a phase II...
14.
van Kuilenburg A, Vreken P, Beex L, Meinsma R, van Lenthe H, De Abreu R, et al.
Adv Exp Med Biol
. 1998 May;
431:293-8.
PMID: 9598078
No abstract available.
15.
Paridaens R, Roy J, Nooij M, KLIJN J, Houston S, Beex L, et al.
Anticancer Drugs
. 1998 Mar;
9(1):29-35.
PMID: 9491789
Vorozole (Rivizor) is a potent and stereospecific inhibitor of aromatase having shown promising endocrine effects in phase I studies. In the present trial, 27 postmenopausal patients with advanced breast cancer,...
16.
van Kuilenburg A, Vreken P, Beex L, Meinsma R, van Lenthe H, De Abreu R, et al.
Eur J Cancer
. 1998 Feb;
33(13):2258-64.
PMID: 9470816
Dihydropyrimidine dehydrogenase (DPD) is responsible for the breakdown of the widely used antineoplastic agent 5-fluorouracil (5-FU), thereby limiting the efficacy of the therapy. It has been suggested that patients suffering...
17.
Vogels M, Tjan-Heijnen V, Alkemade J, Beex L, Muytjens H
Acta Derm Venereol
. 1997 May;
77(3):222-4.
PMID: 9188876
Erythematous nodular and ulcerating skin lesions occurred in a 56-year-old woman treated with chemotherapy and glucocorticosteroids for metastatic breast cancer. Subsequent culture yielded Mycobacterium abscessus, a facultative pathogen which exists...
18.
van Dijck J, Verbeek A, Beex L, Hendriks J, Holland R, Mravunac M, et al.
Int J Cancer
. 1997 Jan;
70(2):164-8.
PMID: 9009155
Recent case-referent studies in the Nijmegen breast-screening programme have shown a reduction in breast-cancer mortality of approximately 50% due to screening of women aged 65 years and older. In this...
19.
van Dijck J, Verbeek A, Beex L, Hendriks J, Holland R, Mravunac M, et al.
Int J Cancer
. 1996 Jun;
66(6):727-31.
PMID: 8647640
We evaluated whether regular mammographic screening of women aged 65 years or older affected breast cancer mortality. In Nijmegen, a population-based screening program for breast cancer was started in 1975,...
20.
Hermans J, Beex L, Blijham G, Cleton F, Sleeboom H, Papapoulos S
Eur J Cancer
. 1996 Mar;
32A(3):450-4.
PMID: 8814691
The effect of pamidronate treatment on the first development of bone metastases was investigated in 124 patients with breast cancer, with either locally advanced disease (n = 33) or extraskeletal...